An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05009680` - A Single and Repeat Dose Trial in Participants With Hepatic Impairment	Phase 1/Phase 2
Recruiting	`NCT04494269` - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls	Phase 1
Terminated	`NCT05517226` - Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment	Phase 1
Completed	`NCT03983161` - A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment	Phase 1
Completed	`NCT04546789` - Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK	Phase 1
Completed	`NCT03282513` - A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function	Phase 1
Recruiting	`NCT05976321` - A Study of TAK-279 in Adults With or Without Liver Damage	Phase 1
Completed	`NCT04473664` - A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment	Phase 1
Recruiting	`NCT05484206` - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434	Phase 1
Completed	`NCT03290443` - A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.	Phase 1
Completed	`NCT02245243` - Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment	Phase 1
Completed	`NCT02244827` - Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment	Phase 1
Completed	`NCT02004587` - Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers	Phase 1
Completed	`NCT01621633` - A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers	Phase 2
Completed	`NCT01493869` - Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects	Phase 1
Completed	`NCT04482270` - A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function	Phase 1
Completed	`NCT02115347` - Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)	Phase 1
Completed	`NCT06161259` - Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment	Phase 1
Completed	`NCT05481411` - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment	Phase 1
Completed	`NCT05409911` - A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants	Phase 1

NCT number	NCT04950764
Study type	Interventional
Source	CymaBay Therapeutics, Inc.
Contact	Barry Crittenden, MD
Phone	510-293-8800
Email	medinfo@cymabay.com
Status	Recruiting
Phase	Phase 1
Start date	September 17, 2021
Completion date	June 2024

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms